Strs Ohio bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 236,425 shares of the conglomerate's stock, valued at approximately $48,467,000.
A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp raised its stake in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock worth $1,303,163,000 after purchasing an additional 579,046 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Trading Down 0.8%
Shares of DHR stock opened at $192.85 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The stock has a market capitalization of $138.09 billion, a P/E ratio of 41.03, a price-to-earnings-growth ratio of 2.71 and a beta of 0.75. The company has a 50 day moving average price of $201.62 and a 200 day moving average price of $199.15.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the business posted $1.72 EPS. The firm's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.
Danaher Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is 27.23%.
Insider Buying and Selling
In other Danaher news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of research firms have recently issued reports on DHR. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Robert W. Baird boosted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. UBS Group reduced their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Guggenheim reissued a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Barclays reissued an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $246.35.
Get Our Latest Stock Report on DHR
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
